| 李 翔,任昊芹,孙 亮,岳 鹏,吕 鹏.腰痹通胶囊联合塞来昔布胶囊治疗椎间盘源性腰痛的疗效及对血清炎性因子和疼痛介质的影响[J].,2023,(13):2450-2453 |
| 腰痹通胶囊联合塞来昔布胶囊治疗椎间盘源性腰痛的疗效及对血清炎性因子和疼痛介质的影响 |
| Efficacy of Yaobitong Capsule Combined with Celecoxib Capsule in the Treatment of Discogenic Low Back Pain and its Influence on Serum Inflammatory Factors and Pain Mediators |
| 投稿时间：2022-12-24 修订日期：2023-01-20 |
| DOI：10.13241/j.cnki.pmb.2023.13.010 |
| 中文关键词: 腰痹通胶囊 塞来昔布胶囊 椎间盘源性腰痛 疗效 炎性因子 疼痛介质 |
| 英文关键词: Yaobitong capsule Celecoxib capsule Discogenic low back pain Efficacy Inflammatory factors Pain mediators |
| 基金项目:北京市自然科学基金项目（L172015） |
|
| 摘要点击次数: 699 |
| 全文下载次数: 531 |
| 中文摘要: |
| 摘要 目的：探讨腰痹通胶囊联合塞来昔布胶囊治疗椎间盘源性腰痛（DLBP）的疗效及对血清炎性因子和疼痛介质的影响。方法：选择2017年5月~2022年5月期间我院接收的75例DLBP患者。依据信封抽签法将患者分为对照组（n=37）和研究组（n=38），对照组接受塞来昔布胶囊治疗，研究组接受腰痹通胶囊联合塞来昔布胶囊治疗。对比两组疗效、临床症状评分、血清炎性因子和疼痛介质的变化情况，同时观察两组用药安全性。结果：研究组痊愈8例，显效10例，有效18例，临床总有效率94.74%，高于对照组的痊愈4例，显效8例，有效17例，临床总有效率78.38%（P<0.05）。治疗1个月后，研究组的视觉疼痛模拟（VAS）评分、Oswestry功能障碍指数（ODI）较对照组更低（P<0.05），改良日本骨科协会（JOA）评分较对照组更高（P<0.05）。治疗1个月后，研究组的血清白细胞介素-6（IL-6）、C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）水平较对照组更低（P<0.05）。治疗1个月后，研究组的血清 P物质（SP）、多巴胺（DA）、前列腺素E2（PGE2）水平较对照组更低（P<0.05）。两组不良反应发生率组间对比差异不显著（P>0.05）。结论：腰痹通胶囊联合塞来昔布胶囊治疗DLBP，可有效减轻疼痛，恢复腰椎功能，降低血清炎性因子和疼痛介质水平。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the efficacy of Yaobitong capsule combined with celecoxib capsule on discogenic low back pain (DLBP) and its influence on serum inflammatory factors and pain mediators. Methods: 75 patients with DLBP who were admitted to our hospital from May 2017 to May 2022 were selected. Patients were divided into control group (n=37) and study group (n=38) according to envelope lottery method. The control group received celecoxib capsule treatment, and the study group received Yaobitong capsule combined with celecoxib capsule treatment. The efficacy, clinical symptom score, serum inflammatory factors and pain mediators in the two groups were compared, and the drug safety in the two groups was observed. Results: In the study group, 8 cases were cured, 10 cases were effective, 18 cases were effective, and the total clinical effective rate was 94.74%, which was higher than that in the control group, 4 cases were cured, 8 cases were effective, 17 cases were effective, and the total clinical effective rate was 78.38% (P<0.05). 1 month after treatment, the visual analogue scale (VAS) score and Oswestry disability index (ODI) score in the study group were lower than those in the control group(P<0.05), and the modified Japanese Orthopaedic Association (JOA) score was higher than that in the control group (P<0.05). 1 month after treatment, the levels of serum interleukin-6(IL-6), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) in the study group were lower than those in the control group (P<0.05). 1 month after treatment, the levels of serum substance P (SP), dopamine (DA) and prostaglandin E2 (PGE2) in the study group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions in the two groups(P>0.05). Conclusion: Yaobitong capsule combined with celecoxib capsule in the treatment of DLBP can effectively relieve pain, restore lumbar function, and reduce the levels of serum inflammatory factors and pain mediators. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
